Completion of sale of common shares in Hansa Medical AB (publ)
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.
Nexttobe AB (”Nexttobe”) has sold 2,800,000 common shares in Hansa Medical AB (publ) (”Hansa Medical”), through an accelerated bookbuilding to Swedish and International institutional investors at a price of SEK 229 per share (“the Placing”).
Following the Placing, Nexttobe owns 6,643,761 common shares in Hansa Medical, representing 17.4 percent of total number of shares and 17.5 percent of total number of votes in Hansa Medical. Subject to customary exceptions or obtaining consent from ABG Sundal Collier, RBC Capital Markets and Skandinaviska Enskilda Banken AB, Nexttobe has agreed to a lock-up period of 120 days, in relation to its remaining shares in Hansa Medical.
ABG Sundal Collier, RBC Capital Markets and Skandinaviska Enskilda Banken acted as joint bookrunners in connection with the placing.
FOR MORE INFORMATION, PLEASE CONTACT:
Erika Kjellberg Eriksson, CEO of Nexttobe, +46 (0) 761 17 18 23
This announcement does not constitute an offer to sell or a solicitation of any offer to buy any securities of Hansa Medical AB (publ) in any jurisdiction where such offer or sale would be unlawful.
Copies of this announcement are not being made and may not be distributed or sent into the United States, Australia, Canada, Japan or any other jurisdiction in which such distribution would be unlawful or would require registration or other measures.
This announcement and the information contained herein are not for distribution in or into the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There will be no public offering of the securities described herein in the United States.
The securities described here in have also not been and will also not be registered under the applicable securities laws of Australia, Canada or Japan and, subject to certain exemptions, may not be offered or sold in or into or for the account or benefit of any person having a registered address in, or located or resident in Australia, Canada or Japan. There will be no public offering of the securities described herein in Australia, Canada or Japan.
This announcement and any other materials in relation to the securities described herein are only directed to (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth companies, and other persons to whom it may be lawfully communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons in (i), (ii) and (iii) above together being referred to as “relevant persons”). The securities described herein are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire the securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on information contained herein.